My Duc Hospital
Ho Chi Minh City, Vietnam
NCT Number: NCT04804020
Fresh embryo transfer is a routine procedure in vitro fertilization (IVF) treatment. Since the first live birth after an IVF-FET (frozen embryo transfer), recent years have seen a dramatic rise in the number of FET cycles. Three endometrial preparation protocols for frozen-thawed embryo transfer, including artificial, natural, modified natural protocol, have been studied and applied to maximize treatment outcomes. However, those methods are being applied empirically as their efficacy and safety are yet to be determined. The objective of this study is to compare the effectiveness and safety of those protocols.
Looking for future studies?
Notify Me18 year–45 year
Female
Interventional
Not applicable
Ho Chi Minh City, Vietnam
This trial will be conducted at My Duc Hospital, Ho Chi Minh City, Viet Nam. Women who are potentially eligible will be provided information about the trial as long as their stimulation cycles are initiated. Screening for eligibility will be performed by treating physicians on day 2 of the menstrual cycle in the subsequent frozen embryo transfer cycles. Patients will be provided a copy of the informed consent documents. Written informed consent will be obtained by the investigator from all women before the enrolment. Women will be randomized (1:1:1) to AC (artificial cycle) or NC (natural cycle), or mNC (modified natural cycle) protocols using block randomization with a variable block size of 6 or 9 by an independent study coordinator via telephone, using a computer-generated random list (block size of 6, or 9).
Artificial protocol The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. In cases where a dominant follicle emerged, serum LH and progesterone will be determined to rule out luteinization. If LH concentrations are <13 IU and progesterone levels <15 nmol/l, luteinization will deem not to have occurred, and FET was performed.
Natural protocol The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patient's uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter to a level of 20 IU/l or more detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
modified Natural protocol The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patient's uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin - hCG (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
Serum progesterone level was also evaluated using the electrochemiluminescence immunoassay (Elecssys Progesterone III, Cobas®, Roche diagnosis, Germany) with a CV of 5.2%.
Serum progesterone was measured at 3 time points:
Frozen embryo transfer:
A maximum of 2 day-3 and one day-5 embryos will be thawed on the day of embryo transfer, three days after the start of progesterone. Two hours after thawing, surviving embryos will be transferred into the uterus under ultrasound guidance using a soft uterine catheter (Gynétics®, Belgium).
A series of progesterone levels evaluation will be performed at three times: (1) at the start of the cycle, (2) Before the time the embryo transfer is scheduled, (3) On the day of embryo transfer.
The blood sample at the start of the cycle will be stored for further epigenetics analysis.
Future babies' health will also be performed separately.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
Time frame: At 24 weeks of gestation
Live birth is defined as the complete expulsion or extraction from a woman of a product of fertilisation, after 24 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heart beat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached. A birth weight of 350 grams or more can be used if gestational age is unknown (twins are a single count).
Time frame: At 2 weeks after embryo placement
Serum ß-hCG ≥25mIU/mL
Time frame: At 5 weeks after embryo placement
Having at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity
Time frame: At 10 weeks after embryo placement
Having at least 1 gestational sac on ultrasound at 12 weeks' gestation with heart beat activity
Time frame: At 3 weeks after embryo placement
Implantation rate is explained as the number of gestational sacs per number of embryos transferred.
Time frame: At 12 weeks of gestation
A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualisation, or histopathology
Time frame: At 20 weeks of gestation
The spontaneous loss of an intra-uterine pregnancy prior to or at 20 completed weeks of gestational age
Time frame: At 22, 28, 32 weeks and 37 weeks of gestation
Multiple definitions, defined as delivery at <24, <28, <32, <37 completed weeks
Time frame: At 3 weeks from the start of treatment cycle
Cycle cancelling due to:
Time frame: At 24 to 28 weeks of gestation
using a 75g oral glucose tolerance test
Time frame: At 20 weeks of gestation or beyond
Pregnancy-induced hypertension, pre-eclampsia and eclampsia
Time frame: At the time of delivery
Weight of singletons and twins
Time frame: At birth
Weight < 2500 gm at birth
Time frame: At birth
Weight < 1500 gm at birth
Time frame: At birth
Weight >4000 gm at birth
Time frame: At birth
Weight >4500 gm at birth
Time frame: At birth
Structural, functional, and genetic anomalies, that occur during pregnancy, and identified antenatally, at birth, or later in life, and require surgical repair of a defect, or are visually evident, or are life-threatening, or cause death. Any congenital anomaly will be included as followed definition of congenital abnormalities in Surveillance of Congenital Anomalies by Division of Birth Defects and Developmental Disabilities, NCBDDD, Centers for Disease Control and Prevention (2020).
Time frame: At birth
The admittance of the newborn to NICU
Time frame: From the start of treatment up to 10 weeks of gestation
Venous thromboembolism is diagnosed after clinical examination, ultrasound scan and blood test
Time frame: At 6 to 8 weeks' gestation
≥1 gestational sac at early pregnancy ultrasound
Time frame: At 24 weeks' gestation
Birth of more than one baby beyond 24 weeks
Time frame: Two year after randomization
Including direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper.
Time frame: At 20 weeks' gestation
The death of a fetus prior to the complete expulsion or extraction from its mother after 20 completed weeks of gestational age. The death is determined by the fact that, after such separation, the fetus does not breathe or show any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles.
Mỹ Đức Hospital
Other
The Effectiveness and Safety of the Three Endometrial Preparation Protocols for Frozen Embryo Transfer Natural Cycle, Modified Natural Cycle and Artificial Cycle: a Randomized Controlled Trial
Acronym: MONART
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06239376
Adenomyosis, Female Urogenital Diseases
Ho Chi Minh City, Vietnam
View Trial DetailsNCT04371783
Frozen Embryo Transfer, IVF
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06563908
Frozen Embryo Transfer, Hysterosalpingography
View Trial DetailsNCT05109676
IVF
Toulouse, France
View Trial Details